Clinical trial
Randomized, Double-blind, Placebo Controlled, Parallel Group, Prospective Clinical Study to Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes
NCT05303857 is registered in ClinicalTrials.gov with University of Erlangen-Nürnberg Medical School as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Double-blind, Placebo Controlled, Parallel Group, Prospective Clinical Study to Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes
- Lead sponsor
- University of Erlangen-Nürnberg Medical School
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- March 3, 2022
- Completion date
- April 17, 2025
- Enrollment
- 107 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.